GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » Equity-to-Asset

Extrawell Pharmaceutical Holdings (HKSE:00858) Equity-to-Asset : 0.86 (As of Sep. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Extrawell Pharmaceutical Holdings's Total Stockholders Equity for the quarter that ended in Sep. 2023 was HK$1,040.52 Mil. Extrawell Pharmaceutical Holdings's Total Assets for the quarter that ended in Sep. 2023 was HK$1,205.00 Mil. Therefore, Extrawell Pharmaceutical Holdings's Equity to Asset Ratio for the quarter that ended in Sep. 2023 was 0.86.

The historical rank and industry rank for Extrawell Pharmaceutical Holdings's Equity-to-Asset or its related term are showing as below:

HKSE:00858' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.59   Med: 0.88   Max: 0.9
Current: 0.86

During the past 13 years, the highest Equity to Asset Ratio of Extrawell Pharmaceutical Holdings was 0.90. The lowest was 0.59. And the median was 0.88.

HKSE:00858's Equity-to-Asset is ranked better than
89.23% of 1086 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs HKSE:00858: 0.86

Extrawell Pharmaceutical Holdings Equity-to-Asset Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Extrawell Pharmaceutical Holdings Equity-to-Asset Chart

Extrawell Pharmaceutical Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 0.90 0.89 0.89 0.89

Extrawell Pharmaceutical Holdings Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.89 0.89 0.89 0.86

Competitive Comparison of Extrawell Pharmaceutical Holdings's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Extrawell Pharmaceutical Holdings's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Extrawell Pharmaceutical Holdings's Equity-to-Asset falls into.



Extrawell Pharmaceutical Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Extrawell Pharmaceutical Holdings's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Equity to Asset (A: Mar. 2023 )=Total Stockholders Equity/Total Assets
=1281.722/1444.874
=0.89

Extrawell Pharmaceutical Holdings's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )=Total Stockholders Equity/Total Assets
=1040.523/1204.998
=0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Extrawell Pharmaceutical Holdings  (HKSE:00858) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Extrawell Pharmaceutical Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Extrawell Pharmaceutical Holdings (HKSE:00858) Business Description

Traded in Other Exchanges
N/A
Address
979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.
Executives
Mao Yumin 2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited 2201 Interest of corporation controlled by you
Ease Gold Investments Limited 2201 Interest of corporation controlled by you
Jnj Investments Ltd 2201 Interest of corporation controlled by you
United Gene Group Ltd 2201 Interest of corporation controlled by you
United Gene Holdings Limited 2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited 2101 Beneficial owner
Xie Yi 2201 Interest of corporation controlled by you
Huang Zhenping 2101 Beneficial owner
United Gene Industry Group Limited 2101 Beneficial owner
Chen Xuhua 2202 Interest of your spouse
Cheng Yong 2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings (HKSE:00858) Headlines

No Headlines